Accuracy of Postoperative Circulating Tumour DNA Surveillance in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Diagnostic Accuracy Meta-Analysis

Background/Objectives: Postoperative circulating tumour DNA (ctDNA) can identify patients at risk of breast cancer recurrence. We estimated the accuracy of serial surveillance in hormone receptor-positive, HER2-negative early breast cancer and examined its implications for intervention trials. Methods: We considered randomised trials and prospective or retrospective cohorts of surgically treated stage I–III disease with linked postoperative ctDNA and recurrence results for the target subtype. The quantitative synthesis required a serial postoperative testing programme and a recoverable two-by-two table. We searched PubMed, checked citations, and reviewed primary publications, supplements and public datasets for evidence available through 6 November 2026. Sensitivity and cutoff-dependent specificity were pooled using separate binomial-normal random-effects models. Results: Nine studies contributed 1,294 patients and 137 documented recurrences, including the TRAK-ER surveillance cohort. Pooled sensitivity for documented recurrence was 86.1% (95% CI 79.7–93.6), and specificity relative to recurrence status at each study cutoff was 93.0% (95% CI 87.8–96.5). Across seven studies with subtype-specific data, the median of study median lead times was 13.0 months (range 7.5–21.0). Accuracy estimates reflected recurrence status at the study-specific reporting cutoffs. Conclusions: Serial ctDNA detected most documented recurrences in the included cohorts. Estimates reflect the assays, sampling schedules and follow-up of selected populations. A positive ctDNA result with negative contemporaneous imaging may identify patients for assessment of eligibility for an interception trial. The time available to start treatment and the clinical benefit of doing so require prospective evaluation.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-12
DOI
https://doi.org/10.20944/preprints202611.1308.v1
Primary Topic
Cancer Genomics and Diagnostics
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Accuracy of Postoperative Circulating Tumour DNA Surveillance in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Diagnostic Accuracy Meta-Analysis

Humaid Obaid Al-Shamsi, Kefah Mokbel, Kinan Mokbel
Preprints.org
Cancer Genomics and Diagnostics
preprint

Accuracy of Postoperative Circulating Tumour DNA Surveillance in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Diagnostic Accuracy Meta-Analysis

Humaid Obaid Al-Shamsi, Kefah Mokbel, Kinan Mokbel
preprint en

Abstract

Background/Objectives: Postoperative circulating tumour DNA (ctDNA) can identify patients at risk of breast cancer recurrence. We estimated the accuracy of serial surveillance in hormone receptor-positive, HER2-negative early breast cancer and examined its implications for intervention trials. Methods: We considered randomised trials and prospective or retrospective cohorts of surgically treated stage I–III disease with linked postoperative ctDNA and recurrence results for the target subtype. The quantitative synthesis required a serial postoperative testing programme and a recoverable two-by-two table. We searched PubMed, checked citations, and reviewed primary publications, supplements and public datasets for evidence available through 6 November 2026. Sensitivity and cutoff-dependent specificity were pooled using separate binomial-normal random-effects models. Results: Nine studies contributed 1,294 patients and 137 documented recurrences, including the TRAK-ER surveillance cohort. Pooled sensitivity for documented recurrence was 86.1% (95% CI 79.7–93.6), and specificity relative to recurrence status at each study cutoff was 93.0% (95% CI 87.8–96.5). Across seven studies with subtype-specific data, the median of study median lead times was 13.0 months (range 7.5–21.0). Accuracy estimates reflected recurrence status at the study-specific reporting cutoffs. Conclusions: Serial ctDNA detected most documented recurrences in the included cohorts. Estimates reflect the assays, sampling schedules and follow-up of selected populations. A positive ctDNA result with negative contemporaneous imaging may identify patients for assessment of eligibility for an interception trial. The time available to start treatment and the clinical benefit of doing so require prospective evaluation.

Preprints.org
Good health and well-being
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon